These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 19060584)

  • 21. Whole-pelvis radiotherapy in combination with interstitial brachytherapy: does coverage of the pelvic lymph nodes improve treatment outcome in high-risk prostate cancer?
    Bittner N; Merrick GS; Wallner KE; Butler WM; Galbreath R; Adamovich E
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1078-84. PubMed ID: 19553031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer.
    Deger S; Boehmer D; Roigas J; Schink T; Wernecke KD; Wiegel T; Hinkelbein W; Budach V; Loening SA
    Eur Urol; 2005 Apr; 47(4):441-8. PubMed ID: 15774239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary causes of death after permanent prostate brachytherapy.
    Bittner N; Merrick GS; Galbreath RW; Butler WM; Wallner KE; Allen ZA; Brammer SG; Moyad M
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):433-40. PubMed ID: 18448268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone.
    Ragde H; Grado GL; Nadir BS
    Arch Esp Urol; 2001 Sep; 54(7):739-47. PubMed ID: 11692443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
    Eggener SE; Roehl KA; Yossepowitch O; Catalona WJ
    J Urol; 2006 Oct; 176(4 Pt 1):1399-403. PubMed ID: 16952643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of perineural invasion on biochemical progression-free survival after prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E
    Urology; 2005 Nov; 66(5):1048-53. PubMed ID: 16286122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer.
    Morris WJ; Keyes M; Palma D; Spadinger I; McKenzie MR; Agranovich A; Pickles T; Liu M; Kwan W; Wu J; Berthelet E; Pai H
    Urology; 2009 Apr; 73(4):860-5; discussion 865-7. PubMed ID: 19168203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension.
    Dattoli M; Wallner K; True L; Cash J; Sorace R
    Urology; 2007 Feb; 69(2):334-7. PubMed ID: 17320673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Three-year results of treatment for prostate cancer with low-dose rate temporary iridium-192 brachytherapy.
    Momma T; Saito S; Toya K; Yorozu A; Dokiya T; Murai M
    Int J Urol; 2006 Mar; 13(3):218-23. PubMed ID: 16643612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biochemical (prostate-specific antigen) relapse-free survival and toxicity after 125I low-dose-rate prostate brachytherapy.
    Khaksar SJ; Laing RW; Henderson A; Sooriakumaran P; Lovell D; Langley SE
    BJU Int; 2006 Dec; 98(6):1210-5. PubMed ID: 17034501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Obesity is not predictive of overall survival following permanent prostate brachytherapy.
    Merrick GS; Galbreath RW; Butler WM; Wallner KE; Allen ZA; Adamovich E
    Am J Clin Oncol; 2007 Dec; 30(6):588-96. PubMed ID: 18091052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma.
    Nurani R; Wallner K; Merrick G; Virgin J; Orio P; True LD
    J Urol; 2007 Nov; 178(5):1968-73; discussion 1973. PubMed ID: 17868717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary Gleason pattern does not impact survival after permanent interstitial brachytherapy for Gleason score 7 prostate cancer.
    Merrick GS; Galbreath RW; Butler WM; Waller KE; Allen ZA; Lief J; Adamovich E
    Cancer; 2007 Jul; 110(2):289-96. PubMed ID: 17549691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer.
    Moyad MA; Merrick GS; Butler WM; Wallner KE; Galbreath RW; Kurko B; Adamovich E
    Urology; 2005 Dec; 66(6):1150-4. PubMed ID: 16360430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts.
    Malaeb BS; Rashid HH; Lotan Y; Khoddami SM; Shariat SF; Sagalowsky AI; McConnell JD; Roehrborn CG; Koeneman KS
    Urol Oncol; 2007; 25(4):291-7. PubMed ID: 17628294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate-specific antigen relapse-free survival in patients with localized prostate cancer treated by brachytherapy.
    Joseph J; Al-Qaisieh B; Ash D; Bottomley D; Carey B
    BJU Int; 2004 Dec; 94(9):1235-8. PubMed ID: 15610096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radical prostatectomy for clinical stage T3a disease.
    Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
    Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer.
    Zelefsky MJ; Chan H; Hunt M; Yamada Y; Shippy AM; Amols H
    J Urol; 2006 Oct; 176(4 Pt 1):1415-9. PubMed ID: 16952647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer control after low-dose-rate prostate brachytherapy performed by a multidisciplinary team with no previous prostate brachytherapy experience.
    McMullen KP; deGuzman AF; McCullough DL; Lee WR
    Urology; 2004 Jun; 63(6):1128-31. PubMed ID: 15183965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.